# PK Study of PT003 and PT001 in Japanese Healthy Subjects

> **NCT02196714** · PHASE1 · COMPLETED · sponsor: **Pearl Therapeutics, Inc.** · enrollment: 24 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** Glycopyrronium and Formoterol Fumarate (GFF) Dose 1
- **DRUG:** Glycopyrronium and Formoterol Fumarate (GFF) Dose 2
- **DRUG:** Glycopyrronium (GP) Dose 1
- **DRUG:** Glycopyrronium (GP) Dose 2

## Key facts

- **NCT ID:** NCT02196714
- **Lead sponsor:** Pearl Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2014-09
- **Final completion:** —
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02196714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02196714, "PK Study of PT003 and PT001 in Japanese Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02196714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*